ARA-290 (cibinetide): neuropathy and repair research
An overview of erythropoietin-derived peptide research without turning orphan-drug development into a wellness claim.
Educational information only — not medical advice. This page does not diagnose conditions, recommend treatment, or replace care from a qualified clinician. The Peptide Center uses an evidence-first editorial process: regulatory sources, trial registries, and peer-reviewed research take priority; uncertainty is stated rather than filled with promises.
ARA-290, also known as cibinetide, is an erythropoietin-derived peptide studied in neuropathy and tissue-protection research, including orphan-drug development pathways. Investigational status and specialized trial populations mean results may not apply to general recovery or performance marketing.
References
- Therapeutic peptides: recent advances in discovery, synthesis, and clinical applications. Signal Transduction and Targeted Therapy, 2022
- ClinicalTrials.gov: Learn about studies
- FDA: The drug development process
Related resources
Continue with curated, same-topic resources from the published library. These links are educational references, not treatment recommendations.
ARA-290
An overview of erythropoietin-derived peptide research without turning orphan-drug development into a wellness claim.
Open resourcePeptide briefBPC-157
A conservative review of what laboratory findings can and cannot tell us about BPC-157.
Open resourcePeptide briefCardiogen
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefCartalax
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourcePeptide briefCurcumin
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefGHK-Cu
How to read the GHK-Cu literature without turning mechanisms or models into clinical promises.
Open resourceArticleKPV: anti-inflammatory tripeptide research
How to read KPV gut-skin and inflammation literature without overstating preclinical findings.
Open resourceArticleMelanotan II: regulatory warnings and risk context
FDA consumer warnings, unapproved status, and why tanning or libido claims are not benign.
Open resource